Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Melinda Soeung(The University of Texas MD Anderson Cancer Center), Pavlos Msaouel(The University of Texas MD Anderson Cancer Center)
Cited by 4